1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)

T Wakatsuki,H Seimiya,S Fukuoka,N Yamamoto,Tetsuo Mashima ,Keisho Chìn ,Hidekazu Hirano ,Izuma Nakayama ,Keiko Minashi ,Kengo Takeuchi ,Hiroki Hara ,Ken Kato ,Akira Ooki ,Sho Kitano ,Mariko Ogura ,Naoko Kurihara ,Naoki Ishizuka ,Daisuke Takahari ,Narikazu Boku ,Kensei Yamaguchi

doi:10.1016/j.annonc.2023.09.1473

1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)

T Wakatsuki, H Seimiya + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.1473

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Oct 1, 2023

#HER2-positive Advanced Gastric Cancer Patients #HER2-positive Gastric Cancer Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)

Full Text